A new publication involving buserelin was released on December 1, 2026. The study, titled "Is there a difference in ovarian hyperstimulation syndrome rates in freeze-all treatment cycles in high-risk patients treated with different GnRH agonist triggers?", appeared in the journal Human Fertility (Cambridge, England).
The publication examines GnRH agonist triggers, including buserelin, in the context of freeze-all treatment cycles for patients identified as high-risk. No specific findings, outcomes, or comparative results were included in the available event data.
This entry reflects the publication record only. The title indicates a focus on ovarian hyperstimulation syndrome rates across different GnRH agonist trigger protocols, but no conclusions can be reported here beyond the existence and title of the study itself.
Readers interested in buserelin's broader regulatory and clinical background can consult the compound overview for additional context.